SEEL - Ascendis downgraded at Oppenheimer Aytu initiated at overweight at Cantor and more in today's analyst action

Oppenheimer is downgrading shares of Ascendis Pharma (ASND) from outperform to perform and removing its $212 price target.Analyst Leland Gershell says that Street estimates for sales of TransCon hGH (lonapegsomatropin) for pediatric growth hormone deficiency, a BLA for which was submitted last year, are high.Cantor is initiating shares of Aytu Bioscience (AYTU) with an overweight rating and a $11 price target.Analyst Jennifer Kim says that company, which just completed a merger with Neos Therapeutics, has built a diversified, growing portfolio of prescription and consumer health products focused on pediatrics.She adds Aytu's transformation "remains underappreciated" and solid execution would drive shares higher.Cantor is also raising its price target on shares of Arvinas (ARVN) to $140 from $121 due to a "data-rich 2H21 that could drive significant value." The stock is one of the firm's top picks for the second half of the year.Although Akouos' (AKUS) 2020 Q4 EPS beat analyst expectations yesterday,

For further details see:

Ascendis downgraded at Oppenheimer, Aytu initiated at overweight at Cantor and more in today's analyst action